Fortrea (NASDAQ:FTRE) Reports Q3 2026 Revenue of $691.5M and Raises Full-Year Guidance as Bookings Momentum Builds

Sonal Goyal

30 October 2026 09:16 PM AEDT

Fortrea (NASDAQ:FTRE) Reports Q3 2026 Revenue of $691.5M and Raises Full-Year Guidance as Bookings Momentum Builds

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Q3 2026 revenues of $691.5 million with a book-to-bill ratio of 1.12x for the quarter and 1.12x trailing 12 months.
Adjusted EBITDA of $58.0 million; adjusted Net Income of $27.9 million, or $0.28 per diluted share.
Free Cash Flow of $52.5 million; cash provided by operations of $60.8 million.
Raised midpoints of full-year Revenue and adjusted EBITDA guidance while narrowing guidance ranges.

Revenue and Bookings Performance

Fortrea Holdings (NASDAQ:FTRE), a leading global contract research organization, reported third quarter 2026 revenues of $691.5 million. The company maintained a book-to-bill ratio of 1.12x for both the quarter and trailing 12 months, indicating that new Business bookings continued to outpace revenue recognition—a positive signal for future revenue conversion.

CEO Anshul Thakral attributed the results to sustained bookings momentum, stronger commercial execution, and continued operational improvements across the company's clinical development organization. Fortrea provides clinical trial management and support services across multiple therapeutic areas, operating as a standalone CRO following its 2023 Spinoff from Labcorp.

Profitability and Cash Flow

Fortrea reported adjusted EBITDA of $58.0 million for Q3 2026, while GAAP net income was $0.6 million, or $0.01 per diluted share. Adjusted net income was $27.9 million, or $0.28 per diluted share, reflecting the adjustments made to exclude amortization, restructuring costs, and other non-recurring items from the GAAP result. Free cash flow was $52.5 million for the quarter, with Operating Cash Flow of $60.8 million.

The improvement in adjusted profitability and free cash flow generation reflects the company's continued focus on Margin expansion and disciplined Capital management. Management noted that targeted investments in early clinical development capabilities and technology are enhancing Fortrea's ability to deliver differentiated value to pharmaceutical and biotech clients across a range of trials.

Strategic Investments in Growth Capabilities

Fortrea is investing in early clinical development and advanced technology capabilities as part of its return-to-growth strategy. These investments are designed to enhance its competitive positioning in therapeutic segments where clients are increasingly seeking differentiated scientific and operational expertise beyond Commodity trial management services.

The company has focused on building stronger client relationships and improving project delivery metrics since its independence, with the goal of translating improved bookings performance into sustained revenue growth and margin expansion. Management highlighted that teams worldwide are embracing the company's strategic direction while continuing to execute effectively for current clients.

Updated Full-Year 2026 Guidance

Based on Q3 performance and confidence in its near-term pipeline, Fortrea raised the midpoints of its full-year 2026 revenue and adjusted EBITDA guidance while narrowing the ranges. This reflected management's view that the company's commercial momentum and operational execution provide sufficient visibility to tighten the year-end outlook.

The combination of a 1.12x trailing 12-month book-to-bill, improving free cash flow, and sequential operating improvement positions Fortrea on a path toward consistent revenue growth and margin recovery as the Backlog accumulated through bookings converts into future revenue recognition quarters.

Fortrea delivered a constructive third quarter in 2026, with a 1.12x book-to-bill ratio, $52.5 million in free cash flow, and the confidence to raise full-year guidance midpoints. As the company converts its sustained bookings momentum into revenue growth and continues investing in early-stage clinical capabilities, the trajectory points toward a more predictable recovery toward normalized CRO profitability.

What was Fortrea's Q3 2026 revenue?

Fortrea reported Q3 2026 revenues of $691.5 million.

What was Fortrea's book-to-bill ratio in Q3 2026?

Fortrea's book-to-bill ratio was 1.12x for Q3 2026 and 1.12x for the trailing 12 months, indicating new bookings exceeded revenue recognized during the period.

What was Fortrea's adjusted EPS in Q3 2026?

Fortrea reported adjusted net income of $27.9 million, or $0.28 per diluted share, for Q3 2026.

Did Fortrea update its full-year 2026 guidance?

Yes, Fortrea raised the midpoints of its full-year 2026 revenue and adjusted EBITDA guidance while narrowing the guidance ranges, reflecting execution confidence.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.